What changed
$PFE — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $14.5B | EPS $0.75 vs $0.72 🟢
💡 Consensus expects Pfizer's post-COVID revenue decline to outweigh pipeline growth, but the 7% operational growth ex-COVID and reaffirmed 2026 guidance indicate a more resilient core business that is being undervalued.
📉 Reward/risk: 2.8:1
🏢 Business Quality: 6/10 - Diversified pharma giant with strong pipeline and oncology expansion, but facing patent cliffs and post-COVID revenue uncertainty.
📊 Valuation: cheap - PE 19.6x on depressed earnings (median vs own history), EV/EBITDA ~9x below large pharma peers (typically 10-12x), FCF yield >10% supporting...
🔮 Catalyst: Q1 2026 earnings report with EPS beat and reaffirmed guidance, highlighting ex-COVID growth momentum
💰 Entry: $25.21, stop $23.5, target $30
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/PFE0619